Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance

Take a look inside the London 2014 Congress


Then register to join us
in Barcelona!


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Corneal collagen cross-linking using riboflavin with different supplements: Dextran vs Methocel

Poster Details

First Author: A.Thorsrud NORWAY

Co Author(s):                        

Abstract Details


To compare corneal collagen crosslinking for keratoconus using Riboflavin with either the traditional Dextran or the newer Methocel as the main supplement.


Department of Ophthalmology, Oslo University Hospital UllevÄl, Oslo, Norway.


Collagen crosslinking for keratoconus using Riboflavin with either Dextran or the Methocel as the main supplement were performed. Main outcome measures were visibility of the demarcation line on anterior optical coherence tomography (Visante OCT) and alterations in densitometry measurements on Scheimflug imagery (Pentacam). The demarcation was analyzed 1 month after CXL and scored by two observers. Densitometry measurements were undertaken preoperative and after 1 and 6 months after CXL.


20 patients in each of two comparative case series were evaluated. Visibility of the demarcation line in the Riboflavin-Dextran group was scored to an average of respectively 1.45 and 1.4. In the Riboflavin-Methocel group the correspondingly visibility scores were 0.85 and 0.77. We could not perform any valid depth evaluation between the two groups due to low visibility of the demarcation line in the Riboflavin-Methocel group. After 1 month densitometry increase was significant higher in the Riboflavin-Dextran group than in the Riboflavin-Methocel group (p=0.038). The results after 6 months are about to be evaluated and will be reported.


After 1 month, there is a higher degree of visibility of the demarcation line and more increase in densitometry measurements after CXL using Riboflavin-Dextran than Riboflavin-Methocel. Clinical implications of these findings may be a weaker CXL effect using Riboflavin-Methocel than the traditional Riboflavin-Dextran. Financial Disclosure-None

Financial Disclosure:


Back to Poster listing